New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 16, 2012
20:41 EDTTEVATeva and Handok partner in Korean pharmaceutical market
Teva Pharmaceutical Industries and Handok Pharmaceuticals announced their agreement to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately USD 14 billion. Under the terms of the agreement, Teva will contribute its global resources, with responsibilities for manufacturing and supplying a wide range of affordable and innovative medicines. Handok’s primary responsibility will be in sales and marketing, distribution, and regulatory affairs. Teva will have a controlling stake in the new business venture, with a profit split of 51%/49% to Teva and Handok, respectively.
News For TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 >>
September 22, 2015
06:20 EDTTEVALeerink reiterates Outperform on Neurocrine after call with neurologists
Leerink analyst Paul Matteis reiterates an Outperform rating on Neurocrine (NBIX) after speaking with two neurologists on the clinical potential of the company's NBI-98854 and Teva's (TEVA) SD-809 for the treatment of Tardive Dyskinesia, Tourette's Syndrome and Huntington's Chorea. Matteis left the call "increasingly optimistic" on the likelihood of NBI-98854 showing Phase III success for Tardive Dyskinesia. The analyst has a $67 price target for shares.
<< 1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use